Foresite Capital Management IV, LLC Diversified Active

Name: Foresite Capital Management IV, LLC Q1 2023 13F Filing | 13F Explorer
Creator: Foresite Capital Management IV, LLC
Published: 2023-05-12

Location: West Hollywood, CA

CIK: 0001704132 · Show all filings

Period: Q1 2023 (← Previous) (Next →)

Filing Date: May 12, 2023

Total Value: $193M (100.0% shares, 0.0% debt)

Holdings (8)

— Kinnate Biopharma Inc. 31.4%

Value $60.45M Shares 9,671,643 Est. Cost $39.78 Unrealized —

PHVS Pharvaris N.V. 13.6%

Value $26.15M Shares 3,246,926 Est. Cost $31.46 Unrealized -72.0%

— Lyell Immunopharma, Inc. 12.2%

Value $23.6M Shares 10,000,000 Est. Cost $16.24 Unrealized —

ACRS Aclaris Therapeutics, Inc. 11.8%

Value $22.72M Shares 2,808,034 Est. Cost $15.18 Unrealized -16.4%

KURA Kura Oncology, Inc. 11.7%

Value $22.62M Shares 1,849,947 Est. Cost $20.39 Unrealized -38.8%

SNDX Syndax Pharmaceuticals, Inc. 9.6%

Value $18.48M Shares 875,000 Est. Cost $22.62 Unrealized +10.0%

— Cymabay Therapeutics, Inc. 8.1%

Value $15.58M Shares 1,787,094 Est. Cost $3.49 Unrealized —

QSI Quantum-Si Incorporated 1.6%

Value $3.117M Shares 1,771,249 Est. Cost $10.48 Unrealized -81.2%

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	Kinnate Biopharma Inc.	9,671,643	$60.45M	31.4%	$39.78	—	COM	49705R105
PHVS	Pharvaris N.V.	3,246,926	$26.15M	13.6%	$31.46	-72.0%	COM	N69605108
—	Lyell Immunopharma, Inc.	10,000,000	$23.6M	12.2%	$16.24	—	COM	55083R104
ACRS	Aclaris Therapeutics, Inc.	2,808,034	$22.72M	11.8%	$15.18	-16.4%	COM	00461U105
KURA	Kura Oncology, Inc.	1,849,947	$22.62M	11.7%	$20.39	-38.8%	COM	50127T109
SNDX	Syndax Pharmaceuticals, Inc.	875,000	$18.48M	9.6%	$22.62	+10.0%	COM	87164F105
—	Cymabay Therapeutics, Inc.	1,787,094	$15.58M	8.1%	$3.49	—	COM	23257D103
QSI	Quantum-Si Incorporated	1,771,249	$3.117M	1.6%	$10.48	-81.2%	COM CL A	74765K105